Share these talks and lectures with your colleagues
Invite colleaguesWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at support@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support support@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support support@hstalks.com
We hope you have enjoyed this limited-length demo talk
This is a limited length demo talk; you may
login
or review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
Topics Covered
- Vaccine pharmacology
- Vaccine immunogenicity
- Vaccine challenge-protection studies
Talk Citation
Sheets, R. (2015, December 31). Vaccine preclinical studies 2 [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved February 19, 2019, from https://hstalks.com/bs/3176/.Publication History
Vaccine preclinical studies 2
Published on December 31, 2015
20 min
You are viewing a talk that is a part of one of our comprehensive courses. Additional learning material: case studies, projects, workshops and recommended reading; multiple choice questions and suggested exam questions with model answers are available on application. Learn more
Other Talks in the Series: Vaccines
Transcript
0:04
Now we're going to move
from the vaccine's
safety aspects
or toxicology,
to the pharmacology aspects,
or proof-of-concept.
This is the flip side of safety.
So safety is the way
we try to identify risks
and assess risks,
and the proof-of-concept studies
or mode-of-action studies,
are how we try to assess
the potential for benefit.
So for drugs,
pharmacology encompasses
the concepts of pharmacokinetics
and pharmacodynamics.
But in fact for vaccines,
those concepts
don't really readily apply
and what we're really trying
to address is the immunological
mechanism for protection.
So we look at
immunogenicity in animals
and if there's a relevant
animal model,
then we try to do studies
of challenge-protection.
And I'll explain those
in more detail in a moment.
Often these types of studies
are research studies.
And in fact, they're rarely,
if ever, performed
in compliance with
good laboratory practices.
So even though they're
intended to support
regulatory decision making
about potential for benefit,
in fact, the fact
that they're not required
to meet these good
laboratory practice regulations
reflects the fact that,
in fact, in the US,
Phase 1 studies
can only be placed
on clinical hold for safety.
And so really the regulatory
decision making,
the precision
around that has to be
on the basis of risk
assessment or safety aspects.